March 1, 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about $940 million) in cash, excluding EliTech’s clinical chemistry business. Bruker expects to close the transaction in the second quarter of this year.
EliTechGroup is headquartered in Turin, Italy, and employs more than 500 people. Its molecular diagnostic business accounts for the majority of the revenues to be acquired. EliTech offers two sample-to-answer molecular diagnostic systems, InGenius and BeGenius, a portfolio of assays for pathogens and viral disease, as well as niche biomedical systems and microbiology products. Its major R&D and operations sites are in Italy, the United States, France, and Germany.
“EliTech’s breadth of testing menu, ease of use, and fast time to result complements Bruker’s novel LiquidArray syndromic panels, specialty fungal infection, tuberculosis, mycobacteria, and HIV MDx portfolio,” Wolfgang Pusch, PhD, president of Bruker’s microbiology and infection diagnostics division, said in a press statement. “The EliTech esoteric molecular diagnostics portfolio is nicely complementary to our MALDI Biotyper microbial identification platform in infectious disease diagnostics, and both together establish Bruker as an innovative and growing tier two infectious disease specialist in the in vitro diagnostics market.”
Upon closing, EliTech is expected to be a standalone business within Bruker’s microbiology and infection diagnostics division, as a part of the Bruker Calid group.